Validation Data Gallery
Tested Applications
| Positive FC detected in | mouse splenocytes |
Recommended dilution
| Application | Dilution |
|---|---|
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
98058-1-RR targets ICOSLG/B7-H2/CD275 in FC applications and shows reactivity with mouse samples.
| Tested Reactivity | mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen | Recombinant protein 相同性解析による交差性が予測される生物種 |
| Full Name | icos ligand |
| Calculated molecular weight | 36 kDa |
| GenBank accession number | NM_015790.3 |
| Gene Symbol | CD275 |
| Gene ID (NCBI) | 50723 |
| RRID | AB_3672205 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purfication |
| UNIPROT ID | Q9JHJ8-1 |
| Storage Buffer | PBS with 0.09% sodium azide , pH 7.3 |
| Storage Conditions | Store at 2 - 8°C. Stable for one year after shipment. |
Background Information
ICOSLG, also known as B7H2 or GL50, is a type I transmembrane glycoprotein belonging to the B7 ligand family. ICOSLG is extensively expressed on professional antigen-presenting cells including B cells, macrophages, and dendritic cells, as well as non-lymphoid cells including mesenchymal stem cells, endothelial cells, fibroblasts, and tumor cells (PMID: 33756276; 35800767). It is a specific ligand for the T-cell-specific cell surface receptor ICOS and acts as a co-stimulatory molecule (PMID: 11023515; 11007762). The interaction of ICOSLG and ICOS plays important roles in the activation, proliferation, differentiation, and cytokine production of T cells as well as in the antibody secretion from B cells during secondary immune responses (PMID: 21851236).
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for ICOSLG/B7-H2/CD275 antibody 98058-1-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |